Dual approach reveals prostate cancer weakness
A research team from the University of Michigan Medical School has developed an innovative treatment strategy for aggressive prostate cancers. This approach involves combining two types of drugs: bromodomain inhibitors and DNA methyltransferase (DNMT) inhibitors. The results demonstrated that this combination significantly halts tumor growth and reverses genetic changes associated with cellular transformation. It works by preventing cancer cells from escaping traditional treatments through interference with pathways that promote alternative cellular identities, as well as restoring the activity of genes that have been lost. Animal trials showed good tolerability. The study plans to identify biomarkers to determine which patient groups would benefit most, as well as explore the potential of applying this method for early prevention of cancer cell transformation and its use against other types of cancers, such as lung and pancreatic cancers.
Notice: This Is an AI-Generated Summary
Comments (0)